The expression of BAFF in the muscles correlate with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies

Yawen Zhao,Wei Zhang,Yilin Liu,Zhaoxia Wang,Yun Yuan

DOI: https://doi.org/10.21203/rs.2.23941/v1

2020-01-01

Abstract:BackgroundAutoimmune necrotizing myopathy with anti-signal recognition particle antibodies (ANM-SRP) is considered as a refractory myositis; some patients respond poorly to conventional immunosuppression，required the treatment of B lymphocyte clearance. We aimed to identify the factors related to refractory ANM-SRP.Results48 patients with ANM-SRP were included to identify the factors related to refractory ANM-SRP. We monitored the clinical symptoms and image changes over 12 months. Refractory ANM-SRP appeared in 32.5% patients, who showed no or minimal improvement after 12 months with steroid therapy. The clinical risk factors for refractory patients were male (19.57, 1.49-256.53), severe muscle weakness (7.51, 41.03-54.88) and concurrent interstitial lung disease (39.70, 3.04-518.38). The fatty infiltration rate of thigh muscles over 3 months was more severe (P=0.022) in refractory patients. Muscles of all patients underwent routine histology, enzyme histochemistry and immunohistochemistry staining. The first antibodies used for immunohistochemistry include anti-B cell activating factor (BAFF) and BAFF receptor (BAFF-R) antibodies. Immunohistochemical staining and western bolt showed that the expression of BAFF and BAFF-R in muscles of the patients were higher than that of the normal controls. The positive BAFF-R cells (P=0.036) and CD19 positive lymphocytes (P=0.002) in refractory patients were higher than in patients with good clinical response to therapy.ConclusionThe expression of BAFF and BAFF-R in muscles of ANM-SRP were upregulated. Male, severe muscle weakness, concurrent interstitial lung disease, quick development of muscle fatty infiltration and more BAFF-R and B-lymphocytes infiltration in muscle indicate a poor response to immunosuppressive therapy.